Article Text
PDF
Abstract
Introduction/Background Advanced stage ovarian cancer treatment includes chemotherapy and surgical debulking of the disease. The introduction of neoadjuvant chemotherapy for the reduction of tumor load followed by interval debulking surgery has shown to have proven survival benefit.3 This study helps elucidate whether a delay of more than 6 weeks between chemotherapy and interval debulking surgery has an impact on progression free survival.
Methodology All women diagnosed with stage III high-grade serous ovarian cancer who received neoadjuvant chemotherapy and underwent subsequent interval debulking surgery from January 2019 to January 2022 were included in this retrospective study. The patients were divided into two groups based on time to surgery more or less than 6 weeks. The endpoint was taken as progression-free survival on follow-up. Survival curves were constructed using the Kaplan-Meier method.
Results 2100 patients were obtained from cancer registry who underwent surgery for ovarian cancer during the time defined in this study. Out of these 118 were identified to fulfill the inclusion criteria. 53 patients underwent surgery within 6 weeks of NACT whereas 65 had surgery at an interval of more than 6 weeks. Overall recurrence rate in this cohort was 64.4%. The rate of recurrence was comparable in the two groups undergoing surgery up to 6 weeks and beyond 6 weeks which was 67.9% and 61.5% respectively. The mean progression free survival was 15 months for patients with surgery done within 6 weeks and 18 months for those who had delayed surgery >6 weeks. This difference was not found to be statistically significant. (P=0.854)
Conclusion Delay from neoadjuvant chemotherapy to interval debulking surgery was not found to impact progression free survival.
Disclosures Conflict of interest and source of funding not applicable.
